Effects of a lipid emulsion containing fish oil on polyunsaturated fatty acid profiles, growth and morbidities in extremely premature infants: A randomized controlled trial
Najm S, Löfqvist C, Hellgren G, Engström E, Lundgren P, Hård AL, Lapillonne A, Sävman K, Nilsson AK, Andersson MX, Smith LEH, Hellström A
Clinical nutrition ESPEN · 120 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Posiblemente financiado por la industria
- Gobierno
- National Eye Institute
- Gobierno
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Gobierno
- NEI NIH HHS
- Gobierno
- NICHD NIH HHS
- Subvenciones
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (P30 HD-018655); National Eye Institute (R24-EY-024864); National Eye Institute (R01EY017017); Eunice Kennedy Shriver National Institute of Child Health and Human Development (U54HD090255)
Según 4 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2017-05-03 · Clin Nutr ESPEN · vol. 20 · págs. 17–23
- Editorial
- Elsevier BV
- Citado
- 139 citas · más que el 99% de estudios similares · 9.3× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 44 trabajos
- Acceso
- Acceso abierto (revista híbrida) · CC-BY-NC-ND
- Áreas de investigación
- Neonatal Respiratory Health Research · Fatty Acid Research and Health · Retinopathy of Prematurity Studies
- Palabras clave
- Retinopathy of prematurity, Necrotizing enterocolitis, Medicine, Fish oil, Bronchopulmonary dysplasia, Eicosapentaenoic acid, Docosahexaenoic acid, Parenteral nutrition, Gestational age, Arachidonic acid, Gastroenterology, Polyunsaturated fatty acid, Respiratory distress, Randomized controlled trial, Sepsis, Fatty acid, Internal medicine, Pregnancy, Surgery, Biochemistry, Biology
- MeSH
- humans, bronchopulmonary dysplasia, retinopathy of prematurity, fat emulsions, intravenous, fatty acids, unsaturated, fish oils, treatment outcome, parenteral nutrition, child development, infant, newborn, female, male, infant, extremely premature
12 autores
- Svetlana Najm🇸🇪University of Gothenburg
- Chatarina Löfqvist🇸🇪 · autor de correspondenciaUniversity of Gothenburg
- Gunnel Hellgren🇸🇪University of Gothenburg
- Eva Engström🇸🇪University of Gothenburg
- Pia Lundgren🇸🇪University of Gothenburg
- Anna‐Lena Hård🇸🇪University of Gothenburg
- Alexandre Lapillonne🇫🇷Délégation Paris 5; Université Paris Cité; Assistance Publique – Hôpitaux de Paris
- Karin Sävman🇸🇪University of Gothenburg
- Anders Nilsson🇸🇪University of Gothenburg
- Mats X. Andersson🇸🇪University of Gothenburg
- Lois E. H. Smith🇺🇸Boston Children's Hospital; Harvard University
- Ann Hellström🇸🇪University of Gothenburg
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background & aims
The purpose of the study was to compare the effects of the parenteral emulsion SMOFlipid®, with 15% fish oil, with Clinoleic® on retinopathy of prematurity (ROP) and other morbidities and growth, and to compare their impact on longitudinal serum levels of fatty acids. Retinopathy of prematurity, other morbidity and growth were correlated with each parenteral lipid supplement.
Methods
Ninety infants born at gestational age ® or Clinoleic®. Two thirds (66%) of the infants received parenteral nutrition for up to 14 days birth (median 8, range 2-14 days), and additional 25% of the infants received for up to 28 days after birth (median 21, range 15-28 days). Cord blood samples and then venous blood samples were obtained at ages 1, 7, 14, and 28 days and at postmenstrual age (PMA) 32, 36, and 40 weeks. Breastmilk was collected at postnatal day 7, and at PMA 32 and 40 weeks. Serum phospholipid and breastmilk total fatty acids were analyzed by gas chromatography-mass spectrometry. Treatment groups were compared with regard to ROP, bronchopulmonary dysplasia, necrotizing enterocolitis, patent ductus arteriosus sepsis and growth between birth and 36 weeks.
Results
Infants on SMOFlipid® had higher fractions of omega-3 LCPUFA eicosapentaenoic acid (EPA) and slightly higher omega-3 LCPUFA docosahexaenoic acid (DHA) fraction and a decreased arachidonic acid (AA) to DHA ratio from one week after birth up to 32 postmenstrual weeks compared to infants on Clinoleic®. Treatment groups did not differ in morbidities or growth.
Conclusion
Supplementation with SMOFlipid® containing 15% fish oil during parenteral nutrition increased EPA substantially, DHA marginally, reduced AA and decreased AA to DHA ratio. It did not reduce morbidity or affect growth. Since extremely preterm infants accumulate a large deficit of DHA and AA, studies on more prolonged or different levels of DHA and AA supplementation are warranted.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC-ND).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.